Triple-negative breast cancer (TNBC), which do not express estrogen receptor α (ERα), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2), accounts for 15% of all breast carcinomas and about 70–80% of basal-like breast cancer [1, 2]. Here, ERBB2 is linked to breast cancer.